Body composition derangements in lung cancer patients treated with first‐line pembrolizumab: A multicentre observational study

Abstract Background While immune checkpoint inhibitors (ICIs) are increasingly reshaping the therapeutic landscape of non‐small‐cell lung cancer (NSCLC), only a limited proportion of patients achieve a relevant and long‐lasting benefit with these treatments, calling for the identification of clinica...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Ilaria Trestini, Lorenzo Belluomini, Alessandra Dodi, Marco Sposito, Alberto Caldart, Dzenete Kadrija, Luca Pasqualin, Silvia Teresa Riva, Ilaria Mariangela Scaglione, Daniela Tregnago, Alice Avancini, Jessica Insolda, Linda Confortini, Miriam Casali, Jessica Menis, Emanuele Vita, Marco Cintoni, Marco Todesco, Gianluca Milanese, Isabella Sperduti, Mirko D'Onofrio, Marco Infante, Marcello Tiseo, Maria Cristina Mele, Giampaolo Tortora, Michele Milella, Emilio Bria, Sara Pilotto
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2024-12-01
Saila:	Journal of Cachexia, Sarcopenia and Muscle
Gaiak:	Body composition Immunotherapy Intermuscular adipose tissue Non‐small‐cell lung cancer Sarcopenia
Sarrera elektronikoa:	https://doi.org/10.1002/jcsm.13568
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!